ArticlePakistan journal of medical sciences
Comparison of efficacy of combination therapy of an Intravitreal injection of bevacizumab and photocoagulation versus Pan Retinal Photocoagulation alone in High risk Proliferative Diabetic Retinopathy.
Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis.Health technology assessment (Winchester, England) · 2025Pooled it
- Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.The Cochrane database of systematic reviews · 2023Pooled it
- Effectiveness of Panretinal Photocoagulation Plus Intravitreal Anti-VEGF Treatment Against PRP Alone for Diabetic Retinopathy: A Systematic Review With Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Outcomes of anti-VEGF therapy compared with conventional interventions in diabetic retinopathy management.Experimental and therapeutic medicine · 2026Article
- Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation versus Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Controlled Trial.Pakistan journal of medical sciences · 2025Article
- VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration.International journal of molecular sciences · 2025Review
- Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review.Journal of biological engineering · 2024Review
- Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial.Frontiers in endocrinology · 2024Article
- Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Management of acute proliferative diabetic retinopathy related complications during the first COVID-19 wave.BMC ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare efficacy of intravitreal bevacizumab augmented with Panretinal photocoagulation versus Panretinal photocoagulation alone in high risk proliferative diabetic retinopathy.
methodsThis is Randomized clinical control trial study conducted at ISRA University Hospital, Hyderabad from July 2018 to December 2018. A total of 76 eyes were randomized into two groups, 38 eyes undergone PRP plus intravitreal bevacizumab, while 38 eyes had PRP alone. Status of neovessels was assessed before and after treatment with the help of fundus fluorescein angiography. Neovessels at disc (NVD's) and neovessels elsewhere (NVE's) were assessed with the disc surface diameter.
resultsSeventy-six eyes were enrolled in this randomized clinical trial into two groups consecutively, that all completed the six months follow-up. In the PRP group mean BCVA (logMAR) worsened significantly from mean 0.30±0.07 to mean 0.40±0.04 at a 30
conclusionIntravitreal Bevacizumab augmented with PRP is more effective in early regression of neovessels in high risk PDR patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.